MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Granted: April 17, 2014
Application Number:
20140105859
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
Granted: April 3, 2014
Application Number:
20140094460
The present invention relates to sodium channel inhibitors of Formula I: in which R1, R2, R3, R4, R5, R6, and R7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.
METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS
Granted: March 27, 2014
Application Number:
20140088304
The invention provides methods and intermediates that are useful for preparing a compound of formula I: and salts thereof.
ANTI-DDR1 ANTIBODIES
Granted: March 27, 2014
Application Number:
20140086913
Provided are antibodies, including functional antibody fragments, that specifically bind to discoidin domain receptors (DDRs), and in particular to DDR1 proteins, as well as uses and method of using such antibodies, including in the detection, diagnosis and treatment of diseases and conditions associated with DDR1.
N-Pyrazole A2A Receptor Agonists
Granted: March 13, 2014
Application Number:
20140073596
2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT
Granted: March 13, 2014
Application Number:
20140072554
The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
Granted: February 27, 2014
Application Number:
20140057863
The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral…
COMPOUNDS FOR THE TREATMENT OF ADDICTION
Granted: February 20, 2014
Application Number:
20140051668
Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a…
SYNTHESIS OF AN ANTIVIRAL COMPOUND
Granted: February 20, 2014
Application Number:
20140051867
The present disclosure provides processes for the preparation of a compound of Formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula.
SYNTHESIS OF AN ANTIVIRAL COMPOUND
Granted: February 20, 2014
Application Number:
20140051866
The present disclosure provides a processes for the preparation of a compound of Formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of Formula I.
ANTIVIRAL COMPOUNDS
Granted: February 20, 2014
Application Number:
20140051656
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
ANTIVIRAL COMPOUNDS
Granted: February 20, 2014
Application Number:
20140051626
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE
Granted: February 13, 2014
Application Number:
20140045818
The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula I.
PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS
Granted: February 6, 2014
Application Number:
20140039194
The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.
ANTIVIRAL COMPOUNDS
Granted: February 6, 2014
Application Number:
20140039021
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
Granted: February 6, 2014
Application Number:
20140037735
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a…
METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT
Granted: February 6, 2014
Application Number:
20140037732
This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.
UNITARY PHARMACEUTICAL DOSAGE FORM
Granted: February 6, 2014
Application Number:
20140037724
In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
INHIBITORS OF FLAVIVIRIDAE VIRUSES
Granted: January 30, 2014
Application Number:
20140030223
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS
Granted: January 30, 2014
Application Number:
20140030356
There is provided a method for treating pulmonary hypertension in a subject, comprising: administering to the subject in need thereof a daily dose of ambrisentan from 1 mg to about 15 mg, wherein the method is carried out without drug labeling instruction to monitor liver aminotransferase levels during ambrisentan treatment.
